Law360, Philadelphia (October 15, 2015, 6:32 PM EDT) -- Trial in a third case over abnormal breast growth allegedly caused by a Johnson & Johnson unit’s antipsychotic drug got underway on Thursday as a Philadelphia jury heard arguments that the pharmaceutical giant had worked to peddle the medication to pediatric doctors despite a lack of approval from federal regulators.
Kline & Specter PC attorney Tom Kline told the jury that improper marketing by Janssen Pharmaceuticals Inc. had led a pediatric neurologist to prescribe Risperdal to an 11-year-old boy to treat symptoms of Tourette dyndrome without...
J&J's Marketing Of Risperdal For Children Slammed In Trial
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
